Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or PDE5 Inhibitor

or Tryptamine

Use the filters below to narrow your results.

None (27) · Anafranil (1) · Aurorix (1) · Cialis, Adcirca (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Levitra, Staxyn (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Stendra (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Viagra, Revatio (1) · Vivactil (1) · Zoloft (1)

5-HT2A agonist (15) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1) · Reversible inhibitor of MAO-A (1) · Selective inhibitor of PDE5 with a substantially longer half-life than other PDE5 inhibitors, allowing once-daily continuous dosing. (1) · Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation. (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (44) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000040-QINU`"' (1) · '"`UNIQ--vote-00000669-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) · '"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1)

None (44) · 10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) · 10 mg ~1 h before sexual activity (1) · 100 mg ~15 min before sexual activity (1) · 25 mg (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1)

None (44) · 2.5, 5, 10, 20 mg tabs (1) · 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · 50, 100, 200 mg tabs (1)

None (44) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 20 mg/d (1) · 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) · 200 mg/d (1) · 200 mg/d (100 mg/d if on CYP3A4 inhibitors) (1)

None (43) · IV (Revatio) (1) · Oral (6)

None (43) · 30 min (1) · 30–60 min (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · ~15 min (fastest of the PDE5 inhibitors) (1) · ~30 min (1)

None (43) · 4–5 h (1) · 4–6 h (1) · Chronic daily dosing (1) · Long (1) · Up to 36 h ("the weekend pill") (1) · ~4 h (1)

None (43) · 4–5 h (1) · ~12 hours (1) · ~17.5 h (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~4 h (1) · ~5 h (1)

None (43) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Rapid absorption; absolute bioavailability not formally established (1) · Reasonable (not formally established as a percentage) (1) · ~15% (extensive hepatic first-pass) (1) · ~40% (1) · ~50% (highly variable) (1)

None (43) · Category B (3) · Category C (1) · Category C (not relevant; not used in women) (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)